Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) fell 14.5% on Monday . The stock traded as low as C$0.27 and last traded at C$0.27. 438,482 shares changed hands during trading, a decline of 36% from the average session volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Up 3.8 %
The stock has a fifty day moving average price of C$0.11 and a two-hundred day moving average price of C$0.08. The company has a market cap of C$23.96 million, a price-to-earnings ratio of -13.75 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- What is a Low P/E Ratio and What Does it Tell Investors?
- Super Micro Computer: Turning Risk Into Reward at the Crossroads
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- After a Reset Year, Is Moderna Stock Poised for a Comeback?
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Retail Trends Spark Analyst Upgrades for DICK’s Sporting Goods
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
